Leuven (Brussels Morning Newspaper): REMYND’s drug REMO046127 showed potential in helping Alzheimer’s by protecting brain cells and lowering harmful proteins. However, a Phase 2a trial was stopped because of liver side effects. Now, they are working on a safer version of the drug that targets similar brain functions.
A new drug called REM0046127 is being studied as a possible treatment for Alzheimer’s disease, according to research by REMYND in Leuven. In tests with mice, the drug protected brain cells from damage and improved communication between them, which is important for memory and thinking. It can also lower two key proteins linked to Alzheimer’s: amyloid plaques, which disrupt cell communication, and tau proteins, which cause tangles inside cells. By targeting these proteins, REM0046127 could help prevent or even repair some brain damage, making it a promising step toward better treatments for the disease.
What’s next for REMYND’s REM0046127 in Alzheimer’s treatment?
ReMYND has begun a phase 2a clinical trial to test the drug REM0046127 in people with early and moderate Alzheimer’s disease. In the study, participants received treatment for 4 weeks, with some getting a placebo and others receiving different doses. It has been said that those who took REM0046127 did much better on memory tests. Brain activity also improved, and higher levels of dopamine were found in their spinal fluid. The amount of tau proteins, which are linked to Alzheimer’s, was lower, showing good results from the treatment.
The study of the drug REM0046127 was stopped because patients had side effects, including liver problems. The company said these issues were not related to how the drug works. Now, researchers are testing a different molecule that should not cause liver problems but hopes to have the same positive effects. This new drug also works on parts of the brain called septin filaments. ReMYND plans to start a phase 1 study of this new drug next year, and patients will be included the year after.
